{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:22:41Z","timestamp":1775323361393,"version":"3.50.1"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,15]]},"DOI":"10.7759\/cureus.60376","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:25:11Z","timestamp":1715822711000},"source":"Crossref","is-referenced-by-count":4,"title":["The Neurological Implications of COVID-19: A Comprehensive Narrative Review"],"prefix":"10.7759","author":[{"given":"Ithamar","family":"Cheyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venmanassery Sreejan","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeharika","family":"Muppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel Emanuel","family":"Armas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Sophia","family":"Gil Agurto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Abhigna","family":"Akula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubhangi","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sheraz","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbusres.2020.06.008","article-title":"Effects of COVID-19 on business and research","volume":"117","author":"Donthu N","year":"2020","unstructured":"Donthu N, Gustafsson A. Effects of COVID-19 on business and research. J Bus Res. 2020, 117:284-9. 10.1016\/j.jbusres.2020.06.008","journal-title":"J Bus Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11020235","article-title":"Long-lasting cognitive abnormalities after COVID-19","volume":"11","author":"Ferrucci R","year":"2021","unstructured":"Ferrucci R, Dini M, Groppo E, et al.. Long-lasting cognitive abnormalities after COVID-19. Brain Sci. 2021, 11:10.3390\/brainsci11020235","journal-title":"Brain Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32275-3","article-title":"Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI","volume":"13","author":"Aj\u010devi\u0107 M","year":"2023","unstructured":"Aj\u010devi\u0107 M, Iscra K, Furlanis G, et al.. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci Rep. 2023, 13:5808. 10.1038\/s41598-023-32275-3","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30142-3","article-title":"The neurological impact of COVID-19","volume":"19","author":"The Lancet Neurology","year":"2020","unstructured":"The Lancet Neurology. The neurological impact of COVID-19. Lancet Neurol. 2020, 19:471. 10.1016\/S1474-4422(20)30142-3","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13010010","article-title":"Acute and post-acute neurological complications of COVID-19","volume":"13","author":"Al-Ramadan A","year":"2021","unstructured":"Al-Ramadan A, Rabab'h O, Shah J, Gharaibeh A. Acute and post-acute neurological complications of COVID-19. Neurol Int. 2021, 13:102-19. 10.3390\/neurolint13010010","journal-title":"Neurol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30221-0","article-title":"Neurological associations of COVID-19","volume":"19","author":"Ellul MA","year":"2020","unstructured":"Ellul MA, Benjamin L, Singh B, et al.. Neurological associations of COVID-19. Lancet Neurol. 2020, 19:767-83. 10.1016\/S1474-4422(20)30221-0","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14329","article-title":"Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2","volume":"27","author":"Vonck K","year":"2020","unstructured":"Vonck K, Garrez I, De Herdt V, Hemelsoet D, Laureys G, Raedt R, Boon P. Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2. Eur J Neurol. 2020, 27:1578-87. 10.1111\/ene.14329","journal-title":"Eur J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2174\/1871527320666210308113457","article-title":"Persons with co-existing neurological disorders: risk analysis, considerations and management in COVID-19 pandemic","volume":"21","author":"Sharma S","year":"2022","unstructured":"Sharma S, Batra S, Gupta S, Sharma VK, Rahman MH, Kamal MA. Persons with co-existing neurological disorders: risk analysis, considerations and management in COVID-19 pandemic. CNS Neurol Disord Drug Targets. 2022, 21:228-34. 10.2174\/1871527320666210308113457","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106349","article-title":"Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review","volume":"200","author":"Kubota T","year":"2021","unstructured":"Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review. Clin Neurol Neurosurg. 2021, 200:106349. 10.1016\/j.clineuro.2020.106349","journal-title":"Clin Neurol Neurosurg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-020-00995-3","article-title":"Global consortium study of neurological dysfunction in COVID-19 (GCS-NeuroCOVID): study design and rationale","volume":"33","author":"Frontera J","year":"2020","unstructured":"Frontera J, Mainali S, Fink EL, et al.. Global consortium study of neurological dysfunction in COVID-19 (GCS-NeuroCOVID): study design and rationale. Neurocrit Care. 2020, 33:25-34. 10.1007\/s12028-020-00995-3","journal-title":"Neurocrit Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01957-4","article-title":"Neurological consequences of COVID-19: what have we learned and where do we go from here?","volume":"17","author":"Jarrahi A","year":"2020","unstructured":"Jarrahi A, Ahluwalia M, Khodadadi H, et al.. Neurological consequences of COVID-19: what have we learned and where do we go from here?. J Neuroinflammation. 2020, 17:286. 10.1186\/s12974-020-01957-4","journal-title":"J Neuroinflammation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.03.062","article-title":"A first case of meningitis\/encephalitis associated with SARS-Coronavirus-2","volume":"94","author":"Moriguchi T","year":"2020","unstructured":"Moriguchi T, Harii N, Goto J, et al.. A first case of meningitis\/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020, 94:55-8. 10.1016\/j.ijid.2020.03.062","journal-title":"Int J Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2008597","article-title":"Neurologic features in severe SARS-CoV-2 infection","volume":"382","author":"Helms J","year":"2020","unstructured":"Helms J, Kremer S, Merdji H, et al.. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020, 382:2268-70. 10.1056\/NEJMc2008597","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30308-2","article-title":"Neuropathology of patients with COVID-19 in Germany: a post-mortem case series","volume":"19","author":"Matschke J","year":"2020","unstructured":"Matschke J, L\u00fctgehetmann M, Hagel C, et al.. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020, 19:919-29. 10.1016\/S1474-4422(20)30308-2","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan R","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020, 367:1444-8. 10.1126\/science.abb2762","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/life14020279","article-title":"The role of furin in the pathogenesis of COVID-19-associated neurological disorders","volume":"14","author":"Ayyubova G","year":"2024","unstructured":"Ayyubova G, Gychka SG, Nikolaienko SI, Alghenaim FA, Teramoto T, Shults NV, Suzuki YJ. The role of furin in the pathogenesis of COVID-19-associated neurological disorders. Life (Basel). 2024, 14:279. 10.3390\/life14020279","journal-title":"Life (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181:271-280.e8. 10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson CB","year":"2022","unstructured":"Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022, 23:3-20. 10.1038\/s41580-021-00418-x","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai Y","year":"2020","unstructured":"Cai Y, Zhang J, Xiao T, et al.. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020, 369:1586-92. 10.1126\/science.abd4251","journal-title":"Science"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12945","article-title":"Proteolytic activation of SARS-CoV-2 spike protein","volume":"66","author":"Takeda M","year":"2022","unstructured":"Takeda M. Proteolytic activation of SARS-CoV-2 spike protein. Microbiol Immunol. 2022, 66:15-23. 10.1111\/1348-0421.12945","journal-title":"Microbiol Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03270-23","article-title":"ACE2 and TMPRSS2 distribution in the respiratory tract of different animal species and its correlation with SARS-CoV-2 tissue tropism","volume":"12","author":"Carossino M","year":"2024","unstructured":"Carossino M, Izadmehr S, Trujillo JD, et al.. ACE2 and TMPRSS2 distribution in the respiratory tract of different animal species and its correlation with SARS-CoV-2 tissue tropism. Microbiol Spectr. 2024, 12:e0327023. 10.1128\/spectrum.03270-23","journal-title":"Microbiol Spectr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou P","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-3. 10.1038\/s41586-020-2012-7","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu R","year":"2020","unstructured":"Lu R, Zhao X, Li J, et al.. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020, 395:565-74. 10.1016\/S0140-6736(20)30251-8","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2020.01.003","article-title":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China","volume":"22","author":"Yu F","year":"2020","unstructured":"Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020, 22:74-9. 10.1016\/j.micinf.2020.01.003","journal-title":"Microbes Infect"},{"key":"ref25","article-title":"SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview","volume":"28","author":"Rabaan AA","year":"2020","unstructured":"Rabaan AA, Al-Ahmed SH, Haque S, et al.. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med. 2020, 28:174-84.","journal-title":"Infez Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri L","year":"2020","unstructured":"Cantuti-Castelvetri L, Ojha R, Pedro LD, et al.. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020, 370:856-60. 10.1126\/science.abd2985","journal-title":"Science"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076253","article-title":"Receptors and cofactors that contribute to SARS-CoV-2 entry: can skin be an alternative route of entry?","volume":"24","author":"Barthe M","year":"2023","unstructured":"Barthe M, Hertereau L, Lamghari N, Osman-Ponchet H, Braud VM. Receptors and cofactors that contribute to SARS-CoV-2 entry: can skin be an alternative route of entry?. Int J Mol Sci. 2023, 24:6253. 10.3390\/ijms24076253","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd3072","article-title":"Neuropilin-1 is a host factor for SARS-CoV-2 infection","volume":"370","author":"Daly JL","year":"2020","unstructured":"Daly JL, Simonetti B, Klein K, et al.. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020, 370:861-5. 10.1126\/science.abd3072","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-023-01187-3","article-title":"SARS-CoV and SARS-CoV-2 display limited neuronal infection and lack the ability to transmit within synaptically connected axons in stem cell-derived human neurons","volume":"30","author":"Luczo JM","year":"2024","unstructured":"Luczo JM, Edwards SJ, Ardipradja K, et al.. SARS-CoV and SARS-CoV-2 display limited neuronal infection and lack the ability to transmit within synaptically connected axons in stem cell-derived human neurons. J Neurovirol. 2024, 30:39-51. 10.1007\/s13365-023-01187-3","journal-title":"J Neurovirol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122236119","article-title":"Tropism of SARS-CoV-2 for human cortical astrocytes","volume":"119","author":"Andrews MG","year":"2022","unstructured":"Andrews MG, Mukhtar T, Eze UC, et al.. Tropism of SARS-CoV-2 for human cortical astrocytes. Proc Natl Acad Sci U S A. 2022, 119:e2122236119. 10.1073\/pnas.2122236119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01831-0","article-title":"SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein","volume":"28","author":"Albornoz EA","year":"2023","unstructured":"Albornoz EA, Amarilla AA, Modhiran N, et al.. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. 2023, 28:2878-93. 10.1038\/s41380-022-01831-0","journal-title":"Mol Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.116","article-title":"Presentation of new onset anosmia during the COVID-19 pandemic","volume":"58","author":"Hopkins C","year":"2020","unstructured":"Hopkins C, Surda P, Kumar N. Presentation of new onset anosmia during the COVID-19 pandemic. Rhinology. 2020, 58:295-8. 10.4193\/Rhin20.116","journal-title":"Rhinology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22587","article-title":"Smell dysfunction: a biomarker for COVID-19","volume":"10","author":"Moein ST","year":"2020","unstructured":"Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020, 10:944-50. 10.1002\/alr.22587","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.05.20048421","article-title":"Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection [PREPRINT]","author":"Menni C","year":"2020","unstructured":"Menni C, Valdes AM, Freidin MB, et al.. Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection [PREPRINT]. MedRxiv. 2020, 10.1101\/2020.04.05.20048421","journal-title":"MedRxiv"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00012.2023","article-title":"Mechanisms of SARS-CoV-2-associated anosmia","volume":"103","author":"Tsukahara T","year":"2023","unstructured":"Tsukahara T, Brann DH, Datta SR. Mechanisms of SARS-CoV-2-associated anosmia. Physiol Rev. 2023, 103:2759-66. 10.1152\/physrev.00012.2023","journal-title":"Physiol Rev"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2125","article-title":"Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia","volume":"77","author":"Politi LS","year":"2020","unstructured":"Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. JAMA Neurol. 2020, 77:1028-9. 10.1001\/jamaneurol.2020.2125","journal-title":"JAMA Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.25.009084","article-title":"Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients [PREPRINT]","author":"Brann DH","year":"2020","unstructured":"Brann DH, Tsukahara T, Weinreb C, Logan DW, Datta SR. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients [PREPRINT]. BioRxiv. 2020, 10.1101\/2020.03.25.009084","journal-title":"BioRxiv"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.31.013268","article-title":"SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium [PREPRINT]","author":"Fodoulian L","year":"2020","unstructured":"Fodoulian L, Tuberosa J, Rossier D, Landis BN, Carleton A, Rodriguez I. SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium [PREPRINT]. BioRxiv. 2020, 10.1101\/2020.03.31.013268","journal-title":"BioRxiv"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.10.027","article-title":"Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb","volume":"184","author":"Khan M","year":"2021","unstructured":"Khan M, Yoo SJ, Clijsters M, et al.. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021, 184:5932-5949.e15. 10.1016\/j.cell.2021.10.027","journal-title":"Cell"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.0c00210","article-title":"Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age","volume":"11","author":"Bilinska K","year":"2020","unstructured":"Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age. ACS Chem Neurosci. 2020, 11:1555-62. 10.1021\/acschemneuro.0c00210","journal-title":"ACS Chem Neurosci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-00758-5","article-title":"Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19","volume":"24","author":"Meinhardt J","year":"2021","unstructured":"Meinhardt J, Radke J, Dittmayer C, et al.. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021, 24:168-75. 10.1038\/s41593-020-00758-5","journal-title":"Nat Neurosci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00591-7","article-title":"The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys","volume":"6","author":"Jiao L","year":"2021","unstructured":"Jiao L, Yang Y, Yu W, et al.. The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys. Signal Transduct Target Ther. 2021, 6:169. 10.1038\/s41392-021-00591-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578288","article-title":"SARS-CoV-2 induces inflammation and intracranial infection through the olfactory epithelium-olfactory bulb pathway in non-human primates","volume":"387","author":"Shimizu S","year":"2024","unstructured":"Shimizu S, Nakayama M, Nguyen CT, et al.. SARS-CoV-2 induces inflammation and intracranial infection through the olfactory epithelium-olfactory bulb pathway in non-human primates. J Neuroimmunol. 2024, 387:578288. 10.1016\/j.jneuroim.2024.578288","journal-title":"J Neuroimmunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00292-021-00920-1","article-title":"Detection methods for SARS-CoV-2 in tissue","volume":"42","author":"von Stillfried S","year":"2021","unstructured":"von Stillfried S, Boor P. Detection methods for SARS-CoV-2 in tissue. Pathologe. 2021, 42:81-8. 10.1007\/s00292-021-00920-1","journal-title":"Pathologe"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.172.4.1127","article-title":"Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain","volume":"172","author":"Perlman S","year":"1990","unstructured":"Perlman S, Evans G, Afifi A. Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain. J Exp Med. 1990, 172:1127-32. 10.1084\/jem.172.4.1127","journal-title":"J Exp Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00229.2022","article-title":"Enteric nervous system as a target and source of SARS-CoV-2 and other viral infections","volume":"325","author":"Valdetaro L","year":"2023","unstructured":"Valdetaro L, Thomasi B, Ricciardi MC, Santos KM, Coelho-Aguiar JM, Tavares-Gomes AL. Enteric nervous system as a target and source of SARS-CoV-2 and other viral infections. Am J Physiol Gastrointest Liver Physiol. 2023, 325:G93-G108. 10.1152\/ajpgi.00229.2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1169740","article-title":"Infection routes, invasion mechanisms, and drug inhibition pathways of human coronaviruses on the nervous system","volume":"17","author":"Sha A","year":"2023","unstructured":"Sha A, Chen H. Infection routes, invasion mechanisms, and drug inhibition pathways of human coronaviruses on the nervous system. Front Neurosci. 2023, 17:1169740. 10.3389\/fnins.2023.1169740","journal-title":"Front Neurosci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02664-z","article-title":"New evidence suggests SARS-CoV-2 neuroinvasion along the nervus terminalis rather than the olfactory pathway","volume":"147","author":"von Bartheld CS","year":"2024","unstructured":"von Bartheld CS, Butowt R. New evidence suggests SARS-CoV-2 neuroinvasion along the nervus terminalis rather than the olfactory pathway. Acta Neuropathol. 2024, 147:10. 10.1007\/s00401-023-02664-z","journal-title":"Acta Neuropathol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01293-2","article-title":"Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders","volume":"28","author":"Tyagi K","year":"2023","unstructured":"Tyagi K, Rai P, Gautam A, et al.. Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders. Eur J Med Res. 2023, 28:307. 10.1186\/s40001-023-01293-2","journal-title":"Eur J Med Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200003","article-title":"Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection","volume":"9","author":"Peluso MJ","year":"2022","unstructured":"Peluso MJ, Sans HM, Forman CA, et al.. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2022, 9:200003. 10.1212\/NXI.0000000000200003","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-024-01576-9","article-title":"Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment","volume":"27","author":"Greene C","year":"2024","unstructured":"Greene C, Connolly R, Brennan D, et al.. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024, 27:421-32. 10.1038\/s41593-024-01576-9","journal-title":"Nat Neurosci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105131","article-title":"The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier","volume":"146","author":"Buzhdygan TP","year":"2020","unstructured":"Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, et al.. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol Dis. 2020, 146:105131. 10.1016\/j.nbd.2020.105131","journal-title":"Neurobiol Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm2052","article-title":"Nervous system consequences of COVID-19","volume":"375","author":"Spudich S","year":"2022","unstructured":"Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022, 375:267-9. 10.1126\/science.abm2052","journal-title":"Science"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11050-w","article-title":"Neuroimmune disorders in COVID-19","volume":"269","author":"Ari\u00f1o H","year":"2022","unstructured":"Ari\u00f1o H, Heartshorne R, Michael BD, Nicholson TR, Vincent A, Pollak TA, Vogrig A. Neuroimmune disorders in COVID-19. J Neurol. 2022, 269:2827-39. 10.1007\/s00415-022-11050-w","journal-title":"J Neurol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2020-0092","article-title":"Neurological involvement of COVID-19: from neuroinvasion and neuroimmune crosstalk to long-term consequences","volume":"32","author":"Septyaningtrias DE","year":"2021","unstructured":"Septyaningtrias DE, Susilowati R. Neurological involvement of COVID-19: from neuroinvasion and neuroimmune crosstalk to long-term consequences. Rev Neurosci. 2021, 32:427-42. 10.1515\/revneuro-2020-0092","journal-title":"Rev Neurosci"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.12.022","article-title":"High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms","volume":"93","author":"Franke C","year":"2021","unstructured":"Franke C, Ferse C, Kreye J, et al.. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021, 93:415-9. 10.1016\/j.bbi.2020.12.022","journal-title":"Brain Behav Immun"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10752-x","article-title":"Association of CNS demyelination and COVID-19 infection: an updated systematic review","volume":"269","author":"Ismail II","year":"2022","unstructured":"Ismail II, Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J Neurol. 2022, 269:541-76. 10.1007\/s00415-021-10752-x","journal-title":"J Neurol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.102","article-title":"Guillain Barre syndrome as a complication of COVID-19: A systematic review","volume":"49","author":"Aladawi M","year":"2022","unstructured":"Aladawi M, Elfil M, Abu-Esheh B, Abu Jazar D, Armouti A, Bayoumi A, Piccione E. Guillain Barre syndrome as a complication of COVID-19: A systematic review. Can J Neurol Sci. 2022, 49:38-48. 10.1017\/cjn.2021.102","journal-title":"Can J Neurol Sci"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123592","article-title":"New onset of autoimmune diseases following COVID-19 diagnosis","volume":"10","author":"Gracia-Ramos AE","year":"2021","unstructured":"Gracia-Ramos AE, Martin-Nares E, Hern\u00e1ndez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021, 10:3592. 10.3390\/cells10123592","journal-title":"Cells"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040774","article-title":"Autoimmune encephalitis in COVID-19 infection: our experience and systematic review of the literature","volume":"10","author":"Stoian A","year":"2022","unstructured":"Stoian A, Stoian M, Bajko Z, et al.. Autoimmune encephalitis in COVID-19 infection: our experience and systematic review of the literature. Biomedicines. 2022, 10:774. 10.3390\/biomedicines10040774","journal-title":"Biomedicines"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05785-z","article-title":"Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19","volume":"43","author":"Payus AO","year":"2022","unstructured":"Payus AO, Jeffree MS, Ohn MH, Tan HJ, Ibrahim A, Chia YK, Raymond AA. Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19. Neurol Sci. 2022, 43:1533-47. 10.1007\/s10072-021-05785-z","journal-title":"Neurol Sci"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2023.0008","article-title":"COVID-19 and autoimmune diseases of the nervous system - an update","volume":"57","author":"Morawiec N","year":"2023","unstructured":"Morawiec N, Adamczyk B, Adamczyk-Sowa M. COVID-19 and autoimmune diseases of the nervous system - an update. Neurol Neurochir Pol. 2023, 57:77-89. 10.5603\/PJNNS.a2023.0008","journal-title":"Neurol Neurochir Pol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103230","article-title":"Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic tachycardia syndrome, autoimmune diseases and autoimmune\/inflammatory syndrome induced by adjuvants","volume":"22","author":"Malkova AM","year":"2023","unstructured":"Malkova AM, Shoenfeld Y. Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic tachycardia syndrome, autoimmune diseases and autoimmune\/inflammatory syndrome induced by adjuvants. Autoimmun Rev. 2023, 22:103230. 10.1016\/j.autrev.2022.103230","journal-title":"Autoimmun Rev"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10837-7","article-title":"Ischemic stroke associated with COVID-19: a systematic review and meta-analysis","volume":"269","author":"Luo W","year":"2022","unstructured":"Luo W, Liu X, Bao K, Huang C. Ischemic stroke associated with COVID-19: a systematic review and meta-analysis. J Neurol. 2022, 269:1731-40. 10.1007\/s00415-021-10837-7","journal-title":"J Neurol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.030335","article-title":"SARS-CoV-2 and stroke in a New York SARS-CoV-2 and stroke in a","volume":"51","author":"Yaghi S","year":"2020","unstructured":"Yaghi S, Ishida K, Torres J, et al.. SARS-CoV-2 and stroke in a New York SARS-CoV-2 and stroke in a. Stroke. 2020, 51:2002-11. 10.1161\/STROKEAHA.120.030335","journal-title":"Stroke"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30272-6","article-title":"COVID-19 related stroke in young individuals","volume":"19","author":"Fifi JT","year":"2020","unstructured":"Fifi JT, Mocco J. COVID-19 related stroke in young individuals. Lancet Neurol. 2020, 19:713-5. 10.1016\/S1474-4422(20)30272-6","journal-title":"Lancet Neurol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin C","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, et al.. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020, 71:762-8. 10.1093\/cid\/ciaa248","journal-title":"Clin Infect Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.03.031","article-title":"Nervous system involvement after infection with COVID-19 and other coronaviruses","volume":"87","author":"Wu Y","year":"2020","unstructured":"Wu Y, Xu X, Chen Z, et al.. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020, 87:18-22. 10.1016\/j.bbi.2020.03.031","journal-title":"Brain Behav Immun"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.031011","article-title":"Early brain imaging shows increased severity of acute ischemic strokes with large vessel occlusion in COVID-19 patients","volume":"51","author":"Escalard S","year":"2020","unstructured":"Escalard S, Chalumeau V, Escalard C, et al.. Early brain imaging shows increased severity of acute ischemic strokes with large vessel occlusion in COVID-19 patients. Stroke. 2020, 51:3366-70. 10.1161\/STROKEAHA.120.031011","journal-title":"Stroke"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000036","article-title":"Diagnosis and management of acute encephalitis: A practical approach","volume":"4","author":"Venkatesan A","year":"2014","unstructured":"Venkatesan A, Geocadin RG. Diagnosis and management of acute encephalitis: A practical approach. Neurol Clin Pract. 2014, 4:206-15. 10.1212\/CPJ.0000000000000036","journal-title":"Neurol Clin Pract"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2020.11.013","article-title":"Encephalopathy and encephalitis during acute SARS-CoV-2 infection. Spanish Society of Neurology COVID-19 Registry","volume":"36","author":"Abenza Abild\u00faa MJ","year":"2021","unstructured":"Abenza Abild\u00faa MJ, Atienza S, Carvalho Monteiro G, et al.. Encephalopathy and encephalitis during acute SARS-CoV-2 infection. Spanish Society of Neurology COVID-19 Registry. Neurologia (Engl Ed). 2021, 36:127-34. 10.1016\/j.nrl.2020.11.013","journal-title":"Neurologia (Engl Ed)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155475","article-title":"SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms","volume":"21","author":"Pennisi M","year":"2020","unstructured":"Pennisi M, Lanza G, Falzone L, Fisicaro F, Ferri R, Bella R. SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms. Int J Mol Sci. 2020, 21:5475. 10.3390\/ijms21155475","journal-title":"Int J Mol Sci"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-021-00796-6","article-title":"A single-cell transcriptomic landscape of the lungs of patients with COVID-19","volume":"23","author":"Wang S","year":"2021","unstructured":"Wang S, Yao X, Ma S, et al.. A single-cell transcriptomic landscape of the lungs of patients with COVID-19. Nat Cell Biol. 2021, 23:1314-28. 10.1038\/s41556-021-00796-6","journal-title":"Nat Cell Biol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01291-6","article-title":"COVID-19-associated monocytic encephalitis (CAME): histological and proteomic evidence from autopsy","volume":"8","author":"Zhang PP","year":"2023","unstructured":"Zhang PP, He ZC, Yao XH, et al.. COVID-19-associated monocytic encephalitis (CAME): histological and proteomic evidence from autopsy. Signal Transduct Target Ther. 2023, 8:24. 10.1038\/s41392-022-01291-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00805","article-title":"Inpatient neurology consultations during the onset of the SARS-CoV-2 New York city pandemic: a single center case series","volume":"11","author":"Radmard S","year":"2020","unstructured":"Radmard S, Epstein SE, Roeder HJ, et al.. Inpatient neurology consultations during the onset of the SARS-CoV-2 New York city pandemic: a single center case series. Front Neurol. 2020, 11:805. 10.3389\/fneur.2020.00805","journal-title":"Front Neurol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0398-3","article-title":"Lifting the mask on neurological manifestations of COVID-19","volume":"16","author":"Pezzini A","year":"2020","unstructured":"Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020, 16:636-44. 10.1038\/s41582-020-0398-3","journal-title":"Nat Rev Neurol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30195-X","article-title":"Real estimates of mortality following COVID-19 infection","volume":"20","author":"Baud D","year":"2020","unstructured":"Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020, 20:773. 10.1016\/S1473-3099(20)30195-X","journal-title":"Lancet Infect Dis"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1159\/000184748","article-title":"The epidemiology of Guillain-Barr\u00e9 syndrome worldwide. A systematic literature review","volume":"32","author":"McGrogan A","year":"2009","unstructured":"McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barr\u00e9 syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009, 32:150-63. 10.1159\/000184748","journal-title":"Neuroepidemiology"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27 Suppl","author":"Asbury AK","year":"1990","unstructured":"Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome. Ann Neurol. 1990, 27 Suppl:S21-4. 10.1002\/ana.410270707","journal-title":"Ann Neurol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar JJ","year":"2011","unstructured":"Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011, 36:123-33. 10.1159\/000324710","journal-title":"Neuroepidemiology"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02301-0","article-title":"Autoantibody screening in Guillain-Barr\u00e9 syndrome","volume":"18","author":"Lleix\u00e0 C","year":"2021","unstructured":"Lleix\u00e0 C, Mart\u00edn-Aguilar L, Pascual-Go\u00f1i E, et al.. Autoantibody screening in Guillain-Barr\u00e9 syndrome. J Neuroinflammation. 2021, 18:251. 10.1186\/s12974-021-02301-0","journal-title":"J Neuroinflammation"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2017.12.003","article-title":"Parkinson's disease pathogenesis, evolution and alternative pathways: A review","volume":"174","author":"Alexoudi A","year":"2018","unstructured":"Alexoudi A, Alexoudi I, Gatzonis S. Parkinson's disease pathogenesis, evolution and alternative pathways: A review. Rev Neurol (Paris). 2018, 174:699-704. 10.1016\/j.neurol.2017.12.003","journal-title":"Rev Neurol (Paris)"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28170","article-title":"Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study","volume":"35","author":"Cilia R","year":"2020","unstructured":"Cilia R, Bonvegna S, Straccia G, et al.. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study. Mov Disord. 2020, 35:1287-92. 10.1002\/mds.28170","journal-title":"Mov Disord"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","article-title":"Clinical course of multiple sclerosis","volume":"8","author":"Klineova S","year":"2018","unstructured":"Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018, 8:a028928. 10.1101\/cshperspect.a028928","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.1.80-94.2006","article-title":"Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease","volume":"19","author":"Fujinami RS","year":"2006","unstructured":"Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006, 19:80-94. 10.1128\/CMR.19.1.80-94.2006","journal-title":"Clin Microbiol Rev"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1038\/488595a","article-title":"Immunology: licensed in the lungs","volume":"488","author":"Ransohoff RM","year":"2012","unstructured":"Ransohoff RM. Immunology: licensed in the lungs. Nature. 2012, 488:595-6. 10.1038\/488595a","journal-title":"Nature"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: Therapeutic implications","volume":"19","author":"Moser T","year":"2020","unstructured":"Moser T, Akg\u00fcn K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: Therapeutic implications. Autoimmun Rev. 2020, 19:102647. 10.1016\/j.autrev.2020.102647","journal-title":"Autoimmun Rev"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050684","article-title":"COVID-19 and multiple sclerosis: a complex relationship possibly aggravated by low vitamin D levels","volume":"12","author":"Fernandes de Souza WD","year":"2023","unstructured":"Fernandes de Souza WD, Fonseca DM, Sartori A. COVID-19 and multiple sclerosis: a complex relationship possibly aggravated by low vitamin D levels. Cells. 2023, 12:684. 10.3390\/cells12050684","journal-title":"Cells"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T cells in multiple sclerosis","volume":"8","author":"Kaskow BJ","year":"2018","unstructured":"Kaskow BJ, Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb Perspect Med. 2018, 8:a029025. 10.1101\/cshperspect.a029025","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323020","article-title":"Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19","volume":"70","author":"Yeoh YK","year":"2021","unstructured":"Yeoh YK, Zuo T, Lui GC, et al.. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021, 70:698-706. 10.1136\/gutjnl-2020-323020","journal-title":"Gut"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson KV","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019, 19:477-89. 10.1038\/s41577-019-0165-0","journal-title":"Nat Rev Immunol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12477","article-title":"Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)","volume":"27","author":"Barclay W","year":"2017","unstructured":"Barclay W, Shinohara ML. Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Brain Pathol. 2017, 27:213-9. 10.1111\/bpa.12477","journal-title":"Brain Pathol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients","volume":"218","author":"Rodrigues TS","year":"2021","unstructured":"Rodrigues TS, de S\u00e1 KS, Ishimoto AY, et al.. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021, 218:e20201707. 10.1084\/jem.20201707","journal-title":"J Exp Med"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102915","article-title":"COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect?","volume":"51","author":"Etemadifar M","year":"2021","unstructured":"Etemadifar M, Sedaghat N, Aghababaee A, et al.. COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect?. Mult Scler Relat Disord. 2021, 51:102915. 10.1016\/j.msard.2021.102915","journal-title":"Mult Scler Relat Disord"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041672","article-title":"COVID-19-related neuropathic pain: a systematic review and meta-analysis","volume":"12","author":"Williams LD","year":"2023","unstructured":"Williams LD, Zis P. COVID-19-related neuropathic pain: a systematic review and meta-analysis. J Clin Med. 2023, 12:1672. 10.3390\/jcm12041672","journal-title":"J Clin Med"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.660087","article-title":"Elucidating the neuropathologic mechanisms of SARS-CoV-2 infection","volume":"12","author":"Pacheco-Herrero M","year":"2021","unstructured":"Pacheco-Herrero M, Soto-Rojas LO, Harrington CR, et al.. Elucidating the neuropathologic mechanisms of SARS-CoV-2 infection. Front Neurol. 2021, 12:660087. 10.3389\/fneur.2021.660087","journal-title":"Front Neurol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14721","article-title":"Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection","volume":"28","author":"Assini A","year":"2021","unstructured":"Assini A, Gandoglia I, Damato V, Rikani K, Evoli A, Del Sette M. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection. Eur J Neurol. 2021, 28:3537-9. 10.1111\/ene.14721","journal-title":"Eur J Neurol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir MK","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018, 36:253-60. 10.1016\/j.ncl.2018.01.002","journal-title":"Neurol Clin"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-022-00516-3","article-title":"The relationship between myasthenia gravis and COVID-19: a systematic review","volume":"58","author":"Tugasworo D","year":"2022","unstructured":"Tugasworo D, Kurnianto A, Retnaningsih, Andhitara Y, Ardhini R, Budiman J. The relationship between myasthenia gravis and COVID-19: a systematic review. Egypt J Neurol Psychiatr Neurosurg. 2022, 58:83. 10.1186\/s41983-022-00516-3","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2020.04.004","article-title":"Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network","volume":"176","author":"Sol\u00e9 G","year":"2020","unstructured":"Sol\u00e9 G, Salort-Campana E, Pereon Y, et al.. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris). 2020, 176:507-15. 10.1016\/j.neurol.2020.04.004","journal-title":"Rev Neurol (Paris)"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2021.100332","article-title":"Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a National Referral Hospital in Indonesia","volume":"23","author":"Octaviana F","year":"2021","unstructured":"Octaviana F, Yugo HP, Safri AY, Indrawati LA, Wiratman W, Ayuningtyas T, Hakim M. Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a National Referral Hospital in Indonesia. eNeurologicalSci. 2021, 23:100332. 10.1016\/j.ensci.2021.100332","journal-title":"eNeurologicalSci"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03400-9","article-title":"Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes","volume":"24","author":"van Paassen J","year":"2020","unstructured":"van Paassen J, Vos JS, Hoekstra EM, Neumann KM, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020, 24:696. 10.1186\/s13054-020-03400-9","journal-title":"Crit Care"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho AE","year":"2020","unstructured":"Camelo-Filho AE, Silva AM, Estephan EP, et al.. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol. 2020, 11:1053. 10.3389\/fneur.2020.01053","journal-title":"Front Neurol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14951","article-title":"Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival","volume":"28","author":"Jakub\u00edkov\u00e1 M","year":"2021","unstructured":"Jakub\u00edkov\u00e1 M, T\u00fdblov\u00e1 M, Tesa\u0159 A, et al.. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021, 28:3418-25. 10.1111\/ene.14951","journal-title":"Eur J Neurol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28084","article-title":"SARS-CoV- 2: at the crossroad between aging and neurodegeneration","volume":"35","author":"Lippi A","year":"2020","unstructured":"Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV- 2: at the crossroad between aging and neurodegeneration. Mov Disord. 2020, 35:716-20. 10.1002\/mds.28084","journal-title":"Mov Disord"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28104","article-title":"Outcome of Parkinson's disease patients affected by COVID-19","volume":"35","author":"Antonini A","year":"2020","unstructured":"Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's disease patients affected by COVID-19. Mov Disord. 2020, 35:905-8. 10.1002\/mds.28104","journal-title":"Mov Disord"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-020-10102-5","article-title":"Drooling in Parkinson's disease: prevalence and progression from the Non-motor International Longitudinal Study","volume":"35","author":"van Wamelen DJ","year":"2020","unstructured":"van Wamelen DJ, Leta V, Johnson J, et al.. Drooling in Parkinson's disease: prevalence and progression from the Non-motor International Longitudinal Study. Dysphagia. 2020, 35:955-61. 10.1007\/s00455-020-10102-5","journal-title":"Dysphagia"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.52965\/001c.39576","article-title":"Clinically relevant drug interactions with monoamine oxidase inhibitors","volume":"10","author":"Edinoff AN","year":"2022","unstructured":"Edinoff AN, Swinford CR, Odisho AS, et al.. Clinically relevant drug interactions with monoamine oxidase inhibitors. Health Psychol Res. 2022, 10:39576. 10.52965\/001c.39576","journal-title":"Health Psychol Res"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102163","article-title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment","volume":"42","author":"Rejdak K","year":"2020","unstructured":"Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020, 42:102163. 10.1016\/j.msard.2020.102163","journal-title":"Mult Scler Relat Disord"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.925641","article-title":"SARS-CoV-2-associated acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year-old woman without comorbidities: a case report","volume":"21","author":"Ghosh R","year":"2020","unstructured":"Ghosh R, Dubey S, Finsterer J, Chatterjee S, Ray BK. SARS-CoV-2-associated acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year-old woman without comorbidities: a case report. Am J Case Rep. 2020, 21:e925641. 10.12659\/AJCR.925641","journal-title":"Am J Case Rep"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker D","year":"2020","unstructured":"Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020, 43:102174. 10.1016\/j.msard.2020.102174","journal-title":"Mult Scler Relat Disord"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102725","article-title":"COVID-19 in ocrelizumab-treated people with multiple sclerosis","volume":"49","author":"Hughes R","year":"2021","unstructured":"Hughes R, Whitley L, Fitovski K, et al.. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord. 2021, 49:102725. 10.1016\/j.msard.2020.102725","journal-title":"Mult Scler Relat Disord"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-236182","article-title":"Guillain-Barr\u00e9 syndrome following COVID-19: a newly emerging post-infectious complication","volume":"13","author":"Webb S","year":"2020","unstructured":"Webb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barr\u00e9 syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Rep. 2020, 13:10.1136\/bcr-2020-236182","journal-title":"BMJ Case Rep"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000119","article-title":"Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis","volume":"18","author":"Ortiz-Salas P","year":"2016","unstructured":"Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez Q JH. Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis. 2016, 18:1-11. 10.1097\/CND.0000000000000119","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2020-000431","article-title":"Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study","volume":"5","author":"Li Y","year":"2020","unstructured":"Li Y, Li M, Wang M, et al.. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020, 5:279-84. 10.1136\/svn-2020-000431","journal-title":"Stroke Vasc Neurol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2031274","article-title":"Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines","volume":"54","author":"Fernandes Q","year":"2022","unstructured":"Fernandes Q, Inchakalody VP, Merhi M, et al.. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022, 54:524-40. 10.1080\/07853890.2022.2031274","journal-title":"Ann Med"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent developments on therapeutic and diagnostic approaches for COVID-19","volume":"23","author":"Majumder J","year":"2021","unstructured":"Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 2021, 23:14. 10.1208\/s12248-020-00532-2","journal-title":"AAPS J"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05662-9","article-title":"Spectrum of neurological complications following COVID-19 vaccination","volume":"43","author":"Garg RK","year":"2022","unstructured":"Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022, 43:3-40. 10.1007\/s10072-021-05662-9","journal-title":"Neurol Sci"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01267-y","article-title":"Therapeutic approaches to the neurologic manifestations of COVID-19","volume":"19","author":"Graham EL","year":"2022","unstructured":"Graham EL, Koralnik IJ, Liotta EM. Therapeutic approaches to the neurologic manifestations of COVID-19. Neurotherapeutics. 2022, 19:1435-66. 10.1007\/s13311-022-01267-y","journal-title":"Neurotherapeutics"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.040233","article-title":"Incidence of stroke in randomized trials of COVID-19 therapeutics: a systematic review and meta-analysis","volume":"53","author":"Nagraj S","year":"2022","unstructured":"Nagraj S, Varrias D, Hernandez Romero G, et al.. Incidence of stroke in randomized trials of COVID-19 therapeutics: a systematic review and meta-analysis. Stroke. 2022, 53:3410-8. 10.1161\/STROKEAHA.122.040233","journal-title":"Stroke"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105182","article-title":"Care for patients with stroke during the COVID-19 pandemic: physical therapy and rehabilitation suggestions for preventing secondary stroke","volume":"29","author":"Wang CC","year":"2020","unstructured":"Wang CC, Chao JK, Wang ML, et al.. Care for patients with stroke during the COVID-19 pandemic: physical therapy and rehabilitation suggestions for preventing secondary stroke. J Stroke Cerebrovasc Dis. 2020, 29:105182. 10.1016\/j.jstrokecerebrovasdis.2020.105182","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2022.00843","article-title":"Therapeutic trends of cerebrovascular disease during the COVID-19 pandemic and future perspectives","volume":"24","author":"Siegler JE","year":"2022","unstructured":"Siegler JE, Abdalkader M, Michel P, Nguyen TN. Therapeutic trends of cerebrovascular disease during the COVID-19 pandemic and future perspectives. J Stroke. 2022, 24:179-88. 10.5853\/jos.2022.00843","journal-title":"J Stroke"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.3390\/life12020207","article-title":"Pathomechanisms and treatment implications for stroke in COVID-19: a review of the literature","volume":"12","author":"Stamm B","year":"2022","unstructured":"Stamm B, Huang D, Royan R, Lee J, Marquez J, Desai M. Pathomechanisms and treatment implications for stroke in COVID-19: a review of the literature. Life (Basel). 2022, 12:207. 10.3390\/life12020207","journal-title":"Life (Basel)"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323586","article-title":"Characteristics of ischaemic stroke associated with COVID-19","volume":"91","author":"Beyrouti R","year":"2020","unstructured":"Beyrouti R, Adams ME, Benjamin L, et al.. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. 2020, 91:889-91. 10.1136\/jnnp-2020-323586","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2020.100053","article-title":"COVID-19-associated encephalitis successfully treated with combination therapy","volume":"7","author":"Freire-\u00c1lvarez E","year":"2020","unstructured":"Freire-\u00c1lvarez E, Guill\u00e9n L, Lambert K, et al.. COVID-19-associated encephalitis successfully treated with combination therapy. Clin Infect Pract. 2020, 7:100053. 10.1016\/j.clinpr.2020.100053","journal-title":"Clin Infect Pract"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25783","article-title":"Steroid-responsive encephalitis in coronavirus disease 2019","volume":"88","author":"Pilotto A","year":"2020","unstructured":"Pilotto A, Odolini S, Masciocchi S, et al.. Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol. 2020, 88:423-7. 10.1002\/ana.25783","journal-title":"Ann Neurol"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa337","article-title":"Severe COVID-19-related encephalitis can respond to immunotherapy","volume":"143","author":"Cao A","year":"2020","unstructured":"Cao A, Rohaut B, Le Guennec L, et al.. Severe COVID-19-related encephalitis can respond to immunotherapy. Brain. 2020, 143:e102. 10.1093\/brain\/awaa337","journal-title":"Brain"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162575","article-title":"Encephalitis in patients with COVID- 19: a systematic evidence-based analysis","volume":"11","author":"Islam MA","year":"2022","unstructured":"Islam MA, Cavestro C, Alam SS, Kundu S, Kamal MA, Reza F. Encephalitis in patients with COVID- 19: a systematic evidence-based analysis. Cells. 2022, 11:2575. 10.3390\/cells11162575","journal-title":"Cells"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.813487","article-title":"Case report: Anti-LGI1 encephalitis following COVID-19 vaccination","volume":"12","author":"Zlotnik Y","year":"2021","unstructured":"Zlotnik Y, Gadoth A, Abu-Salameh I, Horev A, Novoa R, Ifergane G. Case report: Anti-LGI1 encephalitis following COVID-19 vaccination. Front Immunol. 2021, 12:813487. 10.3389\/fimmu.2021.813487","journal-title":"Front Immunol"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000781","article-title":"Guillain-Barr\u00e9 syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing","volume":"7","author":"Dalakas MC","year":"2020","unstructured":"Dalakas MC. Guillain-Barr\u00e9 syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020, 7:10.1212\/NXI.0000000000000781","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102681","article-title":"Guillain Barr\u00e9 syndrome and COVID-19: Possible role of the cytokine storm","volume":"19","author":"Hussain FS","year":"2020","unstructured":"Hussain FS, Eldeeb MA, Blackmore D, Siddiqi ZA. Guillain Barr\u00e9 syndrome and COVID-19: Possible role of the cytokine storm. Autoimmun Rev. 2020, 19:102681. 10.1016\/j.autrev.2020.102681","journal-title":"Autoimmun Rev"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102246","article-title":"Treatment related fluctuation and response to intravenous immunoglobulin therapy in post COVID-19 Guillain-Barre syndrome","volume":"15","author":"Gupta S","year":"2021","unstructured":"Gupta S, Chandra A, Ray BK, Pandit A. Treatment related fluctuation and response to intravenous immunoglobulin therapy in post COVID-19 Guillain-Barre syndrome. Diabetes Metab Syndr. 2021, 15:102246. 10.1016\/j.dsx.2021.102246","journal-title":"Diabetes Metab Syndr"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117114","article-title":"COVID-19-related and not related Guillain-Barr\u00e9 syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy","volume":"418","author":"Garnero M","year":"2020","unstructured":"Garnero M, Del Sette M, Assini A, et al.. COVID-19-related and not related Guillain-Barr\u00e9 syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. J Neurol Sci. 2020, 418:117114. 10.1016\/j.jns.2020.117114","journal-title":"J Neurol Sci"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_974_22","article-title":"Guillain-Barre syndrome followed by COVID-19 infection, vaccination and other precipitating factors during the pandemic","volume":"26","author":"Martic V","year":"2023","unstructured":"Martic V, Fejzic E, Danilovic M, et al.. Guillain-Barre syndrome followed by COVID-19 infection, vaccination and other precipitating factors during the pandemic. Ann Indian Acad Neurol. 2023, 26:256-60. 10.4103\/aian.aian_974_22","journal-title":"Ann Indian Acad Neurol"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27024","article-title":"COVID-19-associated Guillain-Barr\u00e9 syndrome: The early pandemic experience","volume":"62","author":"Caress JB","year":"2020","unstructured":"Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, Narayanaswami P. COVID-19-associated Guillain-Barr\u00e9 syndrome: The early pandemic experience. Muscle Nerve. 2020, 62:485-91. 10.1002\/mus.27024","journal-title":"Muscle Nerve"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200903115138","article-title":"Targeting COVID-19 in Parkinson\u2019s patients: drugs repurposed","volume":"28","author":"Anwar F","year":"2021","unstructured":"Anwar F, Naqvi S, Al-Abbasi FA, Neelofar N, Kumar V, Sahoo A, Kamal MA. Targeting COVID-19 in Parkinson\u2019s patients: drugs repurposed. Curr Med Chem. 2021, 28:2392-408. 10.2174\/0929867327666200903115138","journal-title":"Curr Med Chem"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-00123-0","article-title":"COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside","volume":"6","author":"Sulzer D","year":"2020","unstructured":"Sulzer D, Antonini A, Leta V, et al.. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020, 6:18. 10.1038\/s41531-020-00123-0","journal-title":"NPJ Parkinsons Dis"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-022-00540-4","article-title":"COVID-19 and Parkinson\u2019s disease: possible links in pathology and therapeutics","volume":"40","author":"Tiwari S","year":"2022","unstructured":"Tiwari S, Yadav N, Singh S. COVID-19 and Parkinson\u2019s disease: possible links in pathology and therapeutics. Neurotox Res. 2022, 40:1586-96. 10.1007\/s12640-022-00540-4","journal-title":"Neurotox Res"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni M","year":"2022","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022, 269:1316-34. 10.1007\/s00415-021-10744-x","journal-title":"J Neurol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-022-01211-9","article-title":"Multiple sclerosis management during the COVID-19 pandemic","volume":"22","author":"Hollen C","year":"2022","unstructured":"Hollen C, Bernard J. Multiple sclerosis management during the COVID-19 pandemic. Curr Neurol Neurosci Rep. 2022, 22:537-43. 10.1007\/s11910-022-01211-9","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"de S\u00e8ze J","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, et al.. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol. 2023, 14:1004795. 10.3389\/fimmu.2023.1004795","journal-title":"Front Immunol"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15554","article-title":"Signs and symptoms of COVID-19 in patients with multiple sclerosis","volume":"29","author":"Schiavetti I","year":"2022","unstructured":"Schiavetti I, Carmisciano L, Ponzano M, et al.. Signs and symptoms of COVID-19 in patients with multiple sclerosis. Eur J Neurol. 2022, 29:3728-36. 10.1111\/ene.15554","journal-title":"Eur J Neurol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis","volume":"78","author":"Salter A","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD, et al.. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol. 2021, 78:699-708. 10.1001\/jamaneurol.2021.0688","journal-title":"JAMA Neurol"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329123","article-title":"Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis","volume":"93","author":"Etemadifar M","year":"2022","unstructured":"Etemadifar M, Nouri H, Pitzalis M, et al.. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. J Neurol Neurosurg Psychiatry. 2022, 93:986-94. 10.1136\/jnnp-2022-329123","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102562","article-title":"Phenotyping post-covid pain as a nociceptive, neuropathic, or nociplastic pain condition","volume":"10","author":"Fern\u00e1ndez-de-Las-Pe\u00f1as C","year":"2022","unstructured":"Fern\u00e1ndez-de-Las-Pe\u00f1as C, Nijs J, Neblett R, et al.. Phenotyping post-covid pain as a nociceptive, neuropathic, or nociplastic pain condition. Biomedicines. 2022, 10:2562. 10.3390\/biomedicines10102562","journal-title":"Biomedicines"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-020-00258-0","article-title":"Pain as clinical manifestations of COVID-19 infection and its management in the pandemic era: a literature review","volume":"56","author":"Widyadharma IP","year":"2020","unstructured":"Widyadharma IP, Sari NN, Pradnyaswari KE, et al.. Pain as clinical manifestations of COVID-19 infection and its management in the pandemic era: a literature review. Egypt J Neurol Psychiatr Neurosurg. 2020, 56:121. 10.1186\/s41983-020-00258-0","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.05.021","article-title":"Chronic pain after COVID-19: implications for rehabilitation","volume":"125","author":"Kemp HI","year":"2020","unstructured":"Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth. 2020, 125:436-40. 10.1016\/j.bja.2020.05.021","journal-title":"Br J Anaesth"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275274","article-title":"Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study","volume":"17","author":"Frontera JA","year":"2022","unstructured":"Frontera JA, Thorpe LE, Simon NM, et al.. Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study. PLoS One. 2022, 17:e0275274. 10.1371\/journal.pone.0275274","journal-title":"PLoS One"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2023.04.021","article-title":"Advances and challenges in neuropathic pain: a narrative review and future directions","volume":"131","author":"Attal N","year":"2023","unstructured":"Attal N, Bouhassira D, Colvin L. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth. 2023, 131:79-92. 10.1016\/j.bja.2023.04.021","journal-title":"Br J Anaesth"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14030332","article-title":"Musculoskeletal and neuropathic pain in COVID-19","volume":"14","author":"Lam CM","year":"2024","unstructured":"Lam CM, Sanderson M, Vu DT, et al.. Musculoskeletal and neuropathic pain in COVID-19. Diagnostics (Basel). 2024, 14:332. 10.3390\/diagnostics14030332","journal-title":"Diagnostics (Basel)"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.2095","article-title":"Precision management of post-COVID pain: An evidence and clinical-based approach","volume":"27","author":"Fern\u00e1ndez-de-Las-Pe\u00f1as C","year":"2023","unstructured":"Fern\u00e1ndez-de-Las-Pe\u00f1as C, Nijs J, Giordano R, Arendt-Nielsen L. Precision management of post-COVID pain: An evidence and clinical-based approach. Eur J Pain. 2023, 27:1107-25. 10.1002\/ejp.2095","journal-title":"Eur J Pain"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05823-w","article-title":"Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review","volume":"43","author":"Rodrigues CL","year":"2022","unstructured":"Rodrigues CL, de Freitas HC, Lima PR, de Oliveira Junior PH, Fernandes JM, D'Almeida JA, N\u00f3brega PR. Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review. Neurol Sci. 2022, 43:2271-6. 10.1007\/s10072-021-05823-w","journal-title":"Neurol Sci"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2021.60.03.21","article-title":"Treatment of myasthenia gravis patients with COVID-19: review of the literature","volume":"60","author":"\u017dupani\u0107 S","year":"2022","unstructured":"\u017dupani\u0107 S, Lazibat I, Rubini\u0107 Majdak M, Jeli\u010di\u0107 M. Treatment of myasthenia gravis patients with COVID-19: review of the literature. Acta Clin Croat. 2022, 60:496-509. 10.20471\/acc.2021.60.03.21","journal-title":"Acta Clin Croat"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107140","article-title":"Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review","volume":"213","author":"Abbas AS","year":"2022","unstructured":"Abbas AS, Hardy N, Ghozy S, et al.. Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review. Clin Neurol Neurosurg. 2022, 213:107140. 10.1016\/j.clineuro.2022.107140","journal-title":"Clin Neurol Neurosurg"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.725967","article-title":"Regulation of angiotensin-converting enzyme 2: a potential target to prevent COVID-19?","volume":"12","author":"Hu Y","year":"2021","unstructured":"Hu Y, Liu L, Lu X. Regulation of angiotensin-converting enzyme 2: a potential target to prevent COVID-19?. Front Endocrinol (Lausanne). 2021, 12:725967. 10.3389\/fendo.2021.725967","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.85985","article-title":"Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1","volume":"13","author":"Han H","year":"2024","unstructured":"Han H, Luo RH, Long XY, et al.. Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1. Elife. 2024, 13:10.7554\/eLife.85985","journal-title":"Elife"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2022.01524","article-title":"Is targeting angiotensin-converting enzyme 2 (ACE2) a prophylactic strategy against COVID-19?","volume":"16","author":"Li J","year":"2022","unstructured":"Li J, Yan Y, Dou F, Gao J. Is targeting angiotensin-converting enzyme 2 (ACE2) a prophylactic strategy against COVID-19?. Biosci Trends. 2022, 16:459-61. 10.5582\/bst.2022.01524","journal-title":"Biosci Trends"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05594-0","article-title":"FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2","volume":"615","author":"Brevini T","year":"2023","unstructured":"Brevini T, Maes M, Webb GJ, et al.. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023, 615:134-42. 10.1038\/s41586-022-05594-0","journal-title":"Nature"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.3c00197","article-title":"Methotrexate inhibits the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain to the host-cell angiotensin-converting enzyme-2 (ACE-2) receptor","volume":"7","author":"Kim SK","year":"2024","unstructured":"Kim SK, Suebka S, Gin A, Nguyen PD, Tang Y, Su J, Goddard WA 3rd. Methotrexate inhibits the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain to the host-cell angiotensin-converting enzyme-2 (ACE-2) receptor. ACS Pharmacol Transl Sci. 2024, 7:348-62. 10.1021\/acsptsci.3c00197","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbad030","article-title":"ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks","volume":"7","author":"Alfaleh MA","year":"2024","unstructured":"Alfaleh MA, Alsulaiman RM, Almahboub SA, et al.. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks. Antib Ther. 2024, 7:53-66. 10.1093\/abt\/tbad030","journal-title":"Antib Ther"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666191119095132","article-title":"Vaccine-associated neurological adverse events: a case report and literature review","volume":"25","author":"Tian M","year":"2020","unstructured":"Tian M, Yang J, Li L, Li J, Lei W, Shu X. Vaccine-associated neurological adverse events: a case report and literature review. Curr Pharm Des. 2020, 25:4570-8. 10.2174\/1381612825666191119095132","journal-title":"Curr Pharm Des"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.3390\/life12091338","article-title":"Safety of COVID-19 Vaccines: Spotlight on Neurological Complications","volume":"12","author":"Tondo G","year":"2022","unstructured":"Tondo G, Virgilio E, Naldi A, Bianchi A, Comi C. Safety of COVID-19 Vaccines: Spotlight on Neurological Complications. Life (Basel). 2022, 12:1338. 10.3390\/life12091338","journal-title":"Life (Basel)"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05427-4","article-title":"Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19","volume":"42","author":"Chen S","year":"2021","unstructured":"Chen S, Fan XR, He S, Zhang JW, Li SJ. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol Sci. 2021, 42:3537-9. 10.1007\/s10072-021-05427-4","journal-title":"Neurol Sci"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1515\/znc-2022-0092","article-title":"Covid-19 vaccines and neurological complications: a systematic review","volume":"78","author":"Allahyari F","year":"2023","unstructured":"Allahyari F, Molaee H, Hosseini Nejad J. Covid-19 vaccines and neurological complications: a systematic review. Z Naturforsch C J Biosci. 2023, 78:1-8. 10.1515\/znc-2022-0092","journal-title":"Z Naturforsch C J Biosci"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S343438","article-title":"Post COVID-19 vaccination-associated neurological complications","volume":"18","author":"Assiri SA","year":"2022","unstructured":"Assiri SA, Althaqafi RM, Alswat K, et al.. Post COVID-19 vaccination-associated neurological complications. Neuropsychiatr Dis Treat. 2022, 18:137-54. 10.2147\/NDT.S343438","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2484","article-title":"Electroencephalographic findings post-COVID-19 vaccination: A systematic review of case reports and case series","volume":"33","author":"Fazlollahi A","year":"2023","unstructured":"Fazlollahi A, Zahmatyar M, Shamekh A, et al.. Electroencephalographic findings post-COVID-19 vaccination: A systematic review of case reports and case series. Rev Med Virol. 2023, 33:e2484. 10.1002\/rmv.2484","journal-title":"Rev Med Virol"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone M","year":"2021","unstructured":"Patone M, Handunnetthi L, Saatci D, et al.. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021, 27:2144-53. 10.1038\/s41591-021-01556-7","journal-title":"Nat Med"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101621","article-title":"NEURO-COVAX: An Italian population-based study of neurological complications after COVID-19 vaccinations","volume":"11","author":"Salsone M","year":"2023","unstructured":"Salsone M, Signorelli C, Oldani A, et al.. NEURO-COVAX: An Italian population-based study of neurological complications after COVID-19 vaccinations. Vaccines (Basel). 2023, 11:1621. 10.3390\/vaccines11101621","journal-title":"Vaccines (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/249147-the-neurological-implications-of-covid-19-a-comprehensive-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:25:17Z","timestamp":1715822717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/249147-the-neurological-implications-of-covid-19-a-comprehensive-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":168,"URL":"https:\/\/doi.org\/10.7759\/cureus.60376","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}